# Case Reports

# Human Colorado tick fever in southern Alberta

Nevio Cimolai, MD, FRCPC Chandar M. Anand, MB, FRCPC George J. Gish, MD Charles H. Calisher, PhD Daniel B. Fishbein, MD

he Colorado tick fever virus has been isolated predominantly in the Rocky Mountain regions of the United States and Canada. Dermacentor andersoni is the usual vector in zoonotic cycles, although other tick species may be involved. Infected vectors have been identified in southern regions of Alberta, British Columbia and Saskatchewan;<sup>1-3</sup> however, we present a case of human infection believed to be the first laboratory-confirmed case in Canada.

## Case report

A 20-year-old woman in southwestern Alberta presented to her physician on May 22, 1986. She had removed a tick from her neck earlier that day. The entire tick had apparently been removed. She was in otherwise good health and denied having travelled during the preceding week, apart from a trip to the nearby Livingstone Range of the Rocky Mountains the day before.

Fever and headache developed 24 to 36 hours after the tick had been noticed; chills, generalized aches, nausea, a stiff neck and hallucinations also occurred. After 48 hours the patient returned to her physician, and penicillin was prescribed. Because the fever and generalized illness continued over the next few days tetracycline was substituted for the penicillin. Five days after the initial presenta-

From the Department of Microbiology and Infectious Diseases, Faculty of Medicine, University of Calgary, the Provincial Laboratory of Public Health, Calgary, the Claresholm Medical Centre, Claresholm, Alta., the Division of Vector-Borne Viral Diseases, Center for Infectious Diseases, Centers for Disease Control, Fort Collins, Colorado, and the Viral and Rickettsial Zoonoses Branch, Division of Viral Diseases, Center for Infectious Diseases, Centers for Disease Control, Atlanta

Reprint requests to: Dr. Chandar M. Anand, Director, Provincial Laboratory of Public Health, PO Box 2490, Calgary, Alta. T2P 2M7 tion the fever remitted, but the patient became increasingly confused and suffered memory loss. A diagnosis of viral encephalitis was considered, and she was transferred to a tertiary care hospital.

The patient was found to be afebrile, oriented and lucid, and the findings at physical examination were unremarkable. She continued to take tetracycline for 10 days and remained well thereafter. Neither a rash nor the return of fever was noted.

Blood samples drawn on admission to hospital revealed a leukocyte count of  $2.4 \times 10^9/L$ . Spirochetes were not observed in a blood smear. Tests on serum samples obtained in the acute and convalescent phases of the illness (May 27 and June 11 respectively) for antibodies to spotted-fever rickettsiae, *Coxiella burnetii, Francisella tularensis, Borrelia burgdorferi, Ehrlichia canis* and Powassan virus gave negative results. The serum obtained June 11 contained significant amounts of antibody to Colorado tick fever virus, as determined by an IgM antibody capture enzyme-linked immunosorbent assay (MACELISA).<sup>4</sup> A serum sample obtained 1 year later had a high titre of neutralizing antibody (Table I).

#### **Comments**

Colorado tick fever is a febrile, usually benign, systemic illness.<sup>5,6</sup> The incubation period averages 4 days but can vary from less than 24 hours to 14 days. The illness may last as long as 1½ weeks, and symptoms can include a biphasic fever, chills, fatigue, headache, myalgia, and ocular and gastrointestinal disorders. Central nervous system (CNS) involvement (e.g., meningitis and encephalitis) has been well documented in children,<sup>5-9</sup> and neck stiffness is seen in up to 20% of adults with this illness.<sup>6</sup> Although the cerebrospinal fluid was not examined in this case, the patient's neck stiffness, hallucinations, disorientation and memory loss suggest that the CNS was involved.

Few physical findings, apart from fever, are

observed; however, a macular rash without well-defined distribution has been seen in about 10% of the cases and may cause physicians to consider a diagnosis of Rocky Mountain spotted fever. Less common presentations include arthritis, hemorrhagic diathesis, carditis, orchitis and pneumonia. <sup>5,6,10,11</sup> The peak incidence is usually from May to July.

Laboratory studies are usually not helpful except in detecting leukopenia. Pleocytosis may be observed in cases of CNS involvement. The diagnosis is confirmed by isolation of the virus from blood or cerebrospinal fluid inoculated into either suckling mice or cell cultures or by serologic techniques, which are more practical in Canada. Blood samples should be collected on or about the day of onset of the illness and then 2 to 3 weeks later and submitted to a local or provincial public health laboratory; a clinical suspicion of Colorado tick fever should be emphasized in the accompanying request.

The replication cycle of the Colorado tick fever virus is maintained between the tick vector *D. andersoni* and various mammals. 12-14 Human infection is acquired from the bite of an infected adult tick. Surveys in British Columbia have documented a low prevalence of seropositivity for complement fixing or neutralizing antibody to Colorado tick fever virus in humans, 15-17 but none of the positive serum samples were from patients with acute disease.

The Colorado tick fever virus and its principal vector have long been recognized in western Canada.<sup>1-3</sup> Although anecdotal reports of suspected infection in humans in Alberta have circulated informally for many years, we believe that the case described here is the first laboratory-confirmed one in Canada and hope that this report will heighten physicians' awareness of this disease in the western provinces. In view of the potentially prolonged incubation period Colorado tick fever may present elsewhere in Canada and should be considered when there is a history of a tick bite and travel to an enzootic area.

Our discussions with Drs. Susan Johnson, Division of Immunology, Foothills Provincial General Hospital, Calgary, Donald McLean, Department of Pathology, University of British Columbia, Vancouver, and Harvey Artsob and Leslie Spence, National Reference Centre for Arbovirology, University of Toronto, were greatly appreciated.

### References

- Brown JH: Colorado tick fever in Alberta. Can J Zool 1955; 33: 389-390
- Eklund CM, Kohls GM, Brennan JM: Distribution of Colorado tick fever and virus-carrying ticks. JAMA 1955; 157: 335–337
- 3. Hall RR, McKiel JA, Gregson JD: Occurrence of Colorado tick fever virus in *Dermacentor andersoni* ticks in British Columbia. *Can J Public Health* 1968; 59: 273-275
- Calisher CH, Poland JD, Calisher SB et al: Diagnosis of Colorado tick fever virus infection by enzyme immunoassays for immunoglobulin M and G antibodies. J Clin Microbiol 1985; 22: 84–88
- Spruance SL, Bailey A: Colorado tick fever: a review of 115 laboratory confirmed cases. Arch Intern Med 1973; 131: 288-293
- Goodpasture HC, Poland JD, Francy DB et al: Colorado tick fever: clinical, epidemiologic, and laboratory aspects of 228 cases in Colorado in 1973–1974. Ann Intern Med 1978; 88: 303–310
- 7. Fraser CH, Schiff DW: Colorado tick fever encephalitis: report of a case. *Pediatrics* 1962; 29: 187-190
- Florio L, Miller MS, Mugrage ER: Colorado tick fever: recovery of virus from human cerebrospinal fluid. J Infect Dis 1952; 91: 285–289
- 9. Silver HK, Meiklejohn G, Kempe CH: Colorado tick fever. Am J Dis Child 1961; 101: 30-36
- Hierholzer WJ, Barry DW: Colorado tick fever pericarditis [C]. JAMA 1971; 217: 825
- Emmons RW, Schade HI: Colorado tick fever simulating acute myocardial infarction. JAMA 1972; 222: 87–88
- Burgdorfer W, Eklund CM: Studies on the ecology of Colorado tick fever virus in western Montana. Am J Hyg 1959; 69: 127–137
- Eklund CM, Kohls GM, Jellison WL: Isolation of Colorado tick fever virus from rodents in Colorado [C]. Science 1958; 128: 413
- Newhouse VF, McKiel JA, Burgdorfer W: California encephalitis, Colorado tick fever and Rocky Mountain spotted fever in eastern Canada: serological evidence. Can J Public Health 1964; 55: 257–261
- 15. Kettyls GD, Verrall VM, Hopper JMH et al: Serological survey of human arbovirus infections in southeastern British Columbia. *Can Med Assoc J* 1968; 99: 600–603
- McLean DM, Chernesky MA, Chernesky SJ et al: Arbovirus prevalence in the East Kootenay region, 1968. Can Med Assoc J 1969; 100: 320–326
- Kettyls GD, Verrall VM, Wilton LD et al: Arbovirus infections in man in British Columbia. Can Med Asoc J 1972; 106: 1175-1179

Date of blood collection	Test results		
	MACELISA*	Complement fixation†	Neutralization test‡
May 27, 1986	1.82	< 8	< 20
June 11, 1986	6.05	< 8	20
July 10, 1987	Not done	Not done	> 640

\*MACELISA = IgM antibody capture enzyme-linked immunosorbent assay. Result expressed as ratio of value for patient's serum to value for normal serum; a ratio of 2.00 or greater is considered to indicate an antibody response to infection.

†Values represent reciprocal of serum dilution.

‡Serum dilution-plaque reduction neutralization test done in Vero cells; values represent reciprocal of serum dilution.